CPIC 2026

活動詳細資訊:

Novotech will be at the CPIC China Pharmaceutical Innovation Conference in Shanghai, meeting with biotech founders and pharma leaders to discuss the future of global drug development. Our team will discuss how we partner with Chinese biotech companies to help advance innovative therapies from early development through global clinical trials, drawing on our expertise across Australia, APAC, North America, and Europe. We'll also share insights on novel modality trials, cross-border study start-up, patient recruitment, data management, and global regulatory strategy.

Join us for these sessions:

• Steven Cha, MD, Therapeutic Strategy Lead: Accelerating Global Value for Advanced Modality Assets in Early Phase Trials. 
  Steven will discuss early-phase oncology strategy for next-generation ADCs, T-cell engagers, trispecifics, and cell and gene therapies, including adaptive dose escalation, biomarker-driven development, specialized site selection, and MRCT planning to support global valuation and out-licensing.
• Tanja Obradovic, PhD, Therapeutic Strategy Lead: Creating Global Value for Early Oncology Assets. 
  Tanja will examine key challenges for novel oncology assets entering clinical development, including regulatory expectations, value creation by modality, accelerated development strategies, and how to strengthen global data packages for assets originating in a single geography.

Other Novotech Attendees:

• Dr. Judith Ng-Cashin, Chief Medical Officer
• Xiaoming Zhang, Vice President, Head of Business Development, APAC
• Andy Liu, Managing Director, Greater China and Global Labs

Visit Booth B26, and please schedule a meeting via the form on this page.